Continuous Temperature Monitoring for Cytokine Release Syndrome

This trial explores whether a small patch called TempTraq can detect fever early to prevent severe cytokine release syndrome (CRS), a condition that may occur after cancer treatment. CRS can cause symptoms such as fever and breathing problems. Participants will wear the patch to continuously monitor their temperature while staying at the NIH clinic. This trial targets adults with cancer receiving specific treatments at the clinic. The goal is to determine if monitoring body temperature can help catch signs of CRS early, potentially preventing serious complications. As an unphased trial, this study allows patients to contribute to innovative research that could enhance the safety of cancer treatments.

The trial information does not specify whether you need to stop taking your current medications. However, if you are on antibiotics for an active infection, you cannot participate in the trial.

Research has shown that using devices like TempTraq for continuous temperature monitoring is generally safe for patients. This method closely tracks body temperature, enabling early detection of potential issues such as cytokine release syndrome (CRS). CRS can occur after cancer treatments and cause symptoms like fever and low blood pressure. Studies indicate that continuous monitoring complements regular checks by adding an extra layer of safety through real-time information.

Researchers are excited about continuous temperature monitoring (CTM) for cytokine release syndrome because it offers a proactive way to manage this serious condition. Unlike traditional methods that react to symptoms after they appear, CTM allows for real-time tracking of temperature changes with devices like TempTraq, which can provide actionable alerts. This means healthcare providers can intervene earlier, potentially preventing severe reactions. Additionally, the option to use black-boxed VitalTraq devices adds another layer of monitoring, which may improve patient outcomes by offering more comprehensive data.

This trial will compare different approaches to continuous temperature monitoring for detecting cytokine release syndrome (CRS). Studies have shown that constant body temperature tracking can help identify fevers earlier in patients at risk of developing CRS, a serious potential side effect of cancer treatments that can cause symptoms like fever and low blood pressure. Participants in the intervention arm will use TempTraq with actionable alerts, which research indicates can detect fevers before they become severe. In studies with similar devices, early fever detection was linked to better management of CRS. This suggests that continuous monitoring could improve patient outcomes by providing timely alerts.¹²⁶⁷⁸